Canada Biosimilars Market Size & Outlook, 2025-2033
Related Markets
Canada biosimilars market highlights
- The Canada biosimilars market generated a revenue of USD 1,202.0 thousand in 2024 and is expected to reach USD 5,712.0 thousand by 2033.
- The Canada market is expected to grow at a CAGR of 19.1% from 2025 to 2033.
- In terms of segment, monoclonal antibodies (mabs) was the largest revenue generating drug class in 2024.
- Insulin & Analogues is the most lucrative drug class segment registering the fastest growth during the forecast period.
Biosimilars market data book summary
| Market revenue in 2024 | USD 1,202.0 thousand |
| Market revenue in 2033 | USD 5,712.0 thousand |
| Growth rate | 19.1% (CAGR from 2025 to 2033) |
| Largest segment | Monoclonal antibodies (mabs) |
| Fastest growing segment | Insulin & Analogues |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD thousand |
| Market segmentation | Monoclonal Antibodies (mAbs), Growth Factors & Hematopoietic Agents, Insulin & Analogues, Osteoporosis / Bone Metabolism Agents, Others Drug Class |
| Key market players worldwide | Amgen Inc, Roche, Sandoz Group AG ADR, Dr. Reddy’s Laboratories, Teva Pharmaceutical Industries Ltd, Pfizer Inc, Samsung Bioepis, Biocon, Viatris Inc, Celltrion Healthcare, AbbVie Inc |
Other key industry trends
- In terms of revenue, Canada accounted for 3.5% of the global biosimilars market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. biosimilars market is projected to lead the regional market in terms of revenue in 2033.
- Mexico is the fastest growing regional market in North America and is projected to reach USD 1,781.1 thousand by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biosimilars Market Scope
Biosimilars Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Sandoz Group AG ADR | View profile | - | - | - |
| Biocon | View profile | 10001+ | Bangalore, Karnataka, India, Asia | http://www.biocon.com |
| Samsung Bioepis | View profile | 501-1000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | https://www.samsungbioepis.com |
| Celltrion Healthcare | View profile | 51-100 | Incheon, Inch'on-jikhalsi, South Korea, Asia | http://www.celltrionhealthcare.com/ |
| Viatris Inc | View profile | 38000 | 1000 Mylan Boulevard, Canonsburg, PA, United States, 15317 | https://www.viatris.com |
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | http://www.roche.com |
| Dr. Reddy’s Laboratories | View profile | 10001+ | Hyderabad, Andhra Pradesh, India, Asia | http://www.drreddys.com/ |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
| Amgen Inc | View profile | 26700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | https://www.amgen.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
Canada biosimilars market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biosimilars market will help companies and investors design strategic landscapes.
Monoclonal antibodies (mabs) was the largest segment with a revenue share of 52.8% in 2024. Horizon Databook has segmented the Canada biosimilars market based on monoclonal antibodies (mabs), growth factors & hematopoietic agents, insulin & analogues, osteoporosis / bone metabolism agents, others drug class covering the revenue growth of each sub-segment from 2021 to 2033.
Rise in initiatives undertaken by the government to enhance adoption of biosimilars is anticipated to fuel market growth in the near future. For instance, in September 2018, the pan-Canadian Pharmaceutical Alliance issued Biologics Policy Directions & pCPA Negotiations, which outline its policies as applied to negotiations for reimbursement of biosimilars and biologics.
In addition, panCanadian Pharmaceutical Alliance collaborated with Cancer Care Ontario to create a pan-Canadian Oncology Biosimilars Initiative aimed at cost-effective and proper implementation of biosimilars in therapeutic oncology.
In addition, initiatives have been undertaken to improve efficiency of funding considerations regarding biosimilars. In June 2019, the Canadian Agency for Drugs and Technologies in Health announced that they would cease reviewing biosimilars through pan-Canadian Oncology Drug Review or the Common Drug Review.
Reasons to subscribe to Canada biosimilars market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Canada biosimilars market databook
-
Our clientele includes a mix of biosimilars market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada biosimilars market , including forecasts for subscribers. This country databook contains high-level insights into Canada biosimilars market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Canada biosimilars market size, by drug class, 2021-2033 (US$K)
Canada Biosimilars Market Outlook Share, 2024 & 2033 (US$K)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
